These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2005-004400-37 TRATAMIENTO DE INDUCCIÓN CON RITUXIMAB + HYPER-CVAD Y ALTAS DOSIS DE METROTREXATO/CITARABINA Y CONSOLIDACIÓN CON Y90-IBRITUMOMAB TIUXETAN EN PACIENTES CON LINFOMA DE CELULAS DEL MANTO bad-data
Ongoing 2005-005110-20 Tratamiento de primera línea del linfoma difuso de célula grande B (LDCGB) con quimioterapia a dosis densas e inmunoterapia (R-CHOP/14) en pacientes mayores de 65 años, y en menores de 65 años de ries... not-yet-due
Ongoing 2006-005254-68 Treatment with R-MegaCHOP and early rescue with R-IFE and autologous stem cells transplant (ASCT) according response measured by positron emission tomography (PET) in patients with diffuse large B-cel... not-yet-due
Completed, but no date, and reported results 2007-003198-22 Trasplante autologo de progenitores hemopoyéticos con acondicionamiento que incluye Zevalin + BEAM en pacientes con linfoma difuso de célula grande B refractario bad-data
Completed, but no date, and reported results 2007-003302-10 Trasplante alogénico de progenitores hematopoyéticos tras acondicionamiento no mieloablativo con melfalan ,fludarabina y zevalin en pacientes con linfoma No Hodgkin B agresivo bad-data
Not reported 2007-006416-32 Trasplante alogénico de progenitores hematopoyéticos de donante no emparentado tras acondicionamiento no mieloablativo e inmunosupresión postrasplante con Rapamicina Alogenic transplantation of unre... 2011-01-11 due-trials
Completed, but no date 2007-006440-22 Ensayo intergrupos (GELTAMO/GETH) Fase II, Abierto, Multicéntrico, de uso de Alemtuzumab (MabCampath®) en Trasplante Alogénico de Donante no Emparentado con Acondicionamiento de Intensidad Reducida en... bad-data
Completed, but no date, and reported results 2008-005687-13 Estudio Fase II abierto prospectivo no aleatorizado para valorar la combinación de rituximab, bendamustina, mitoxantrone, dexametasona (R-BMD) en pacientes con Linfoma Folicular refractarios o en reca... bad-data
Completed, but no date 2008-007305-36 Estudio fase II prospectivo, abierto, multicéntrico de Gemcitabina, Oxaliplatino y Dexametasona + Rituximab en pacientes con linfomas agresivos (difuso de céluls grandes B y del manto) en recaída o re... bad-data
Completed, but no date 2008-007725-39 ESTUDIO MULTICENTRICO FASE II, NO ALEATORIZADO, DE RITUXIMAB EN COMBINACIÓN CON BENDAMUSTINA COMO PRIMER TRATAMIENTO SISTÉMICO EN LINFOMA DE CÉLULAS B DE LA ZONA MARGINAL EXTRAGANGLIONAR DEL TEJIDO L... bad-data
Completed, but no date 2009-016026-13 Estudio de fase II de uso de anticuerpo monoclonal anti-CD20 (ofatumumab) más ESHAP seguido de trasplante autólogo de progenitores hemopoyéticos para el tratamiento de linfoma de Hodgkin clásico en re... bad-data
Completed, but no date 2010-020926-17 Bendamustina, Citarabina, Etopósido y Melfalán como régimen de acondicionamiento para el transplante autólogo de progenitores hematopoyéticos en pacientes con linfoma agresivo bad-data
Ongoing 2011-004729-29 OFATUMUMAB COMO PARTE DEL RÉGIMEN DE ACONDICIONAMIENTO DE INTENSIDAD REDUCIDA (RIC) EN PACIENTES CON LINFOMA B NO-HODGKIN DE ALTO RIESGO QUE RECIBEN UN TRANSPLANTE ALOGÉNICO DE PROGENITORES HEMATOPOYÉ... not-yet-due
Completed, but no date, and reported results 2012-005138-12 Randomized phase II study of treatment with R-CHOP vs Bortezomib-R-CAP for young patients with poor IPI diffuse large B-cell lymphoma. Estudio fase II aleatorizado de tratamiento de los pacientes ... bad-data
Reported results 2013-001065-17 Phase II, randomised, multicentre study with two treatment arms (R-COMP versus R-CHOP) in newly diagnosed elderly patients (?60 years) with non-localised diffuse large B-cell lymphoma (DLBCL)/follicul... 2016-02-17 due-trials
Exempt, with results 2014-000835-17 PHASE I-II CLINICAL TRIAL FOR THE EVALUATION OF THE ROLE OF BRENTUXIMAB VEDOTIN PLUS ETOPOSIDE, SOLUMODERIN, HIGH DOSE ARA-C AND CIS-PLATIN IN THE TRANSPLANT AND POST-TRANSPLANT MANAGEMENT FOR PATIENT... 2019-01-14 not-yet-due
Reported results 2014-001911-38 AN OPEN MULTICENTER PHASE II STUDY OF EFFICACY AND TOXICITY OF MAINTENANCE SUBCUTANEOUS RITUXIMAB AFTER RESCUE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA NON-ELIGIBLE FOR A... 2019-08-14 due-trials
Ongoing 2015-004158-17 Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma. Ensayo clínico Fase II m... not-yet-due
Reported results 2015-005390-21 Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab, gemcitabine, oxaliplatin and dexamethasone followed by Ibrutinib maitenance in patients with... 2021-01-19 due-trials
Exempt 2017-003689-28 A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for Older Patients with Untreated Hodgkin Lymph... not-yet-due
Ongoing 2019-002746-21 A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin’s Lymphoma, Followed by Brentuxima... not-yet-due